Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,044 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

NCT06465316

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
  • Smilow Cancer Hospital Care Center - Guilford Guilford, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
View all 15 locations
View Trial Details
Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) Los Angeles, California, United States
View all 52 locations
View Trial Details
Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

NCT06090539

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Mayo Clinic in Arizona - Phoenix Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Local Institution - 0068 Jacksonville, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 75 locations
View Trial Details
Recruiting

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996

Conditions
B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • University of Alabama At Birmingham Hospital Birmingham, Alabama, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • Ucsf Fresno Fresno, California, United States
  • Kaiser Permanente Southern California Irvine, California, United States
View all 155 locations
View Trial Details
Recruiting

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT07455851

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Prince of Wales Hospital Randwick, New South Wales, Australia
  • Illawarra Cancer care centre, Wollongong Hospital Wollongong, New South Wales, Australia
  • Royal Adelaide Hospital Adelaide, South Australia, Australia
  • Peter MacCallum Cancer Centre Melbourne, Victoria, Australia
View Trial Details
Recruiting

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Beijing GoBroad Hospital Beijing, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, China
  • Shanghai Liquan Hospital Shanghai, China
View Trial Details
Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173

Conditions
B-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations
  • Rigshospitalet ( Site 0802) Copenhagen, Capital Region, Denmark
  • Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804) Aarhus Nord, Central Jutland, Denmark
  • Odense Universitetshospital ( Site 0801) Odense, Region Syddanmark, Denmark
  • Rambam Health Care Campus ( Site 0903) Haifa, Israel
View all 21 locations
View Trial Details

Related conditions